GlassScriptPhysician profile
Edgar R Naut
NPI 1467646166
$3,885.13
in general payments reported to CMS, 2019-2025
28 companies · $683 in 2025
The $683 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $140 · 2021: $580 · 2022: $495 · 2023: $597 · 2024: $868 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.77 |
| Education | $103.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $658.01 | 2019-2024 | Xarelto |
| Pfizer INC. | $361.83 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $342.06 | 2023-2025 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $315.54 | 2020-2025 | Wainua, Farxiga |
| Janssen Biotech, INC. | $295.28 | 2022-2024 | Stelara, Tremfya, Simponi Aria |
| Alexion Pharmaceuticals, INC. | $261.16 | 2021-2025 | Ultomiris, Soliris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.29 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $211.92 | 2019-2025 | |
| Astellas Pharma US INC | $159.01 | 2024 | Cresemba |
| Glaxosmithkline, LLC. | $124.85 | 2019 | |
| Csl Behring | $93.37 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.27 | 2019-2024 | Camzyos |
| Ceribell, INC. | $79.00 | 2025 | Pocket Eeg Device |
| Janssen Scientific Affairs, LLC | $78.78 | 2022 | |
| Eisai INC. | $78.44 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $73.02 | 2023-2024 | Rebyota |
| Alcresta Therapeutics, INC. | $68.02 | 2019-2024 | Relizorb |
| Teva Pharmaceuticals USA, INC. | $63.51 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.75 | 2021 | |
| Ucb, INC. | $39.29 | 2024 | Nayzilam |
| Alnylam Pharmaceuticals INC. | $38.34 | 2025 | |
| Merck Sharp & Dohme LLC | $31.61 | 2019 | |
| Gilead Sciences, INC. | $30.84 | 2020-2021 | |
| Abbvie INC. | $26.34 | 2024 | |
| Amarin Pharma, INC. | $23.77 | 2020 | |
| Mylan Specialty L.P. | $23.77 | 2021 | |
| Genzyme Corporation | $19.07 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.99 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Naut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.